Two Giants Dominate IHE, Making It Riskier Than It Looks
As of March 2026, the iShares U.S. Pharmaceuticals ETF is heavily keyed to two drugmakers, exposing investors to outs...
Get a quick snapshot of today’s dividend ETF expense ratios and what they mean for your potential returns, with tips for comparing funds.
18,562 articlesAs of March 2026, the iShares U.S. Pharmaceuticals ETF is heavily keyed to two drugmakers, exposing investors to outs...
The latest consumer sentiment 56.4 reading sets the tone for retail stocks and the VanEck Retail ETF (RTH) in 2026. I...
Solar’s most hated year is fading into a powerful five-month rally. The Invesco SOLAR ETF has surged roughly 45% sinc...
Income-focused investors are turning to a small group of high-yield energy names that offer cash-flow visibility and ...
Geopolitical tensions and volatile oil prices have investors hunting for stock-wue winners beyond crude. Here are two...
Investors weigh income reliability and risk as markets shift. A $1.5 million portfolio that pays roughly $83,400 annu...
AI is lifting chip demand to new heights. This guide explains the drivers, what the forecast means for investors, and...
A cash-flow driven income approach delivering roughly a 4.4% forward yield is gaining traction as market swings persi...
XRP has pulled back from its highs, trading around $1.44 after a loss from a $3.65 peak. Three major catalysts could ...
This in-depth look at the millionaire interview 473, part reveals tactical money moves from a high-net-worth perspect...
If you’re considering where to put $1,000 right now, Newmont isn’t just about gold — it’s about exposure to a volatil...
Recession fears are resurging, but your best move isn’t to panic. This guide explains why time in the market beats ti...